|
Company:
|
ALLAKOS INC. (ALLK)
|
|
Form Type:
|
4
|
|
Filing Date:
|
3/3/2021
|
|
CIK:
|
0001564824
|
|
Address:
|
975 ISLAND DRIVE
SUITE 201
|
|
City, State, Zip:
|
REDWOOD CITY, California 94065
|
|
Telephone:
|
650-597-5002
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$104.50
|
Change:
-3.64 (-3.37%)
|
Trade Time:
Apr 16
|
Market Cap:
$5.59B
|
|
|
|
|
|
|
Description of Business
|
|
We are a clinical stage biotechnology company developing lirentelimab (AK002),
our wholly owned monoclonal antibody, for the treatment of various mast cell and
eosinophil related diseases. Lirentelimab selectively targets both mast cells
and eosinophils, two types of white blood cells that are widely distributed in
the body and play a central role in the inflammatory response. Inappropriately
activated mast cells and eosinophils have been identified as key drivers in a
number of severe diseases affecting the gastrointestinal tract, eyes, skin,
lungs and other organs. Our initial focus is on eosinophilic gastrointestinal
diseases which include eosinophilic gastritis ("EG"), eosinophilic duodenitis
("EoD") which has also been referred to as eosinophilic gastroenteritis, and
eosinophilic esophagitis ("EoE"); in addition, lirentelimab has the potential to
treat a number of other severe diseases. Lirentelimab has received orphan
disease status for EG, EoD, and EoE from the U.S.
|
|
|
|